Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2010 4
2011 4
2013 1
2014 1
2015 3
2016 1
2017 3
2018 1
2019 5
2020 3
2021 4
2022 5
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Alopecia areata treatment with baricitinib: different relapse phenotypes.
Dall'Oglio F, Nasca MR, Lacarrubba F, Vitale P, Micali G. Dall'Oglio F, et al. Among authors: vitale p. J Dermatolog Treat. 2024 Dec;35(1):2324832. doi: 10.1080/09546634.2024.2324832. Epub 2024 Mar 11. J Dermatolog Treat. 2024. PMID: 38465657 Free article. No abstract available.
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network.
Crispo A, Rivieccio G, Cataldo L, Coluccia S, Luongo A, Coppola E, Grimaldi M, Montagnese C, Nocerino F, D'Errico D, Celentano E, Saviano R, Bastone A, Baglio G, De Angelis C, Ciardiello F, Avallone A, Cassata A, Costanzo R, Morabito A, Maione P, Gridelli C, Cigolari S, Borrelli A, De Placido S, Schiavone F, Bianchi AAM, Pignata S; ValPeROC Group. Crispo A, et al. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13736. doi: 10.1111/ecc.13736. Epub 2022 Oct 25. Eur J Cancer Care (Engl). 2022. PMID: 37039607
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis.
Parisi A, Giampieri R, Mammarella A, Felicetti C, Salvatore L, Bensi M, Maratta MG, Strippoli A, Filippi R, Satolli MA, Petrillo A, Daniele B, De Tursi M, Di Marino P, Giordano G, Landriscina M, Vitale P, Zurlo IV, Dell'Aquila E, Tomao S, Depetris I, Di Pietro FR, Zoratto F, Ciardiello D, Pensieri MV, Garrone O, Galassi B, Ferri C, Berardi R, Ghidini M. Parisi A, et al. Among authors: vitale p. Front Oncol. 2022 Aug 12;12:935826. doi: 10.3389/fonc.2022.935826. eCollection 2022. Front Oncol. 2022. PMID: 36033477 Free PMC article.
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D. Merz V, et al. Among authors: vitale p. Front Surg. 2022 May 4;9:866173. doi: 10.3389/fsurg.2022.866173. eCollection 2022. Front Surg. 2022. PMID: 35599791 Free PMC article. Review.
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti P, Fargnoli MC, Porzio G, Salvatore L, Filippi R, Ghidini M, Nigro O, Gelsomino F, Zurlo IV, Dell'Aquila E, Lombardi P, Keränen SR, Depetris I, Giampieri R, Morelli C, De Tursi M, Di Pietro FR, Zanaletti N, Vitale P, Garajova I, Spinelli GP, Zoratto F, Roberto M, Petrillo A, Aimar G, Cortellini A, Pensieri MV, Ficorella C, Ferri C, Parisi A. Antonetti P, et al. Among authors: vitale p. Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15. Support Care Cancer. 2022. PMID: 34779921
40 results